This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2019 Sep 7;394(10201):830.

doi: 10.1016/S0140-6736(19)31829-X.

Radiotherapy for metastatic prostate cancer-Authors' reply

Christopher C Parker¹, Nicholas D James², Christopher D Brawley³, Noel W Clarke⁴, Mahesh K B Parmar³

Affiliations

Affiliations

¹ Academic Urology Unit, Royal Marsden Hospital, London, SM2 5PT, UK. Electronic address: chris.parker@icr.ac.uk.
² Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
³ Medical Research Council Clinical Trials Unit at University College London, London, UK.
⁴ Genito-Urinary Cancer Research Group, Department of Surgery, The Christie Hospital, Manchester, UK.

PMID: 31498099
DOI: 10.1016/S0140-6736(19)31829-X

Comment

Radiotherapy for metastatic prostate cancer-Authors' reply

Christopher C Parker et al. Lancet. 2019.

. 2019 Sep 7;394(10201):830.

doi: 10.1016/S0140-6736(19)31829-X.

Authors

Christopher C Parker¹, Nicholas D James², Christopher D Brawley³, Noel W Clarke⁴, Mahesh K B Parmar³

Affiliations

¹ Academic Urology Unit, Royal Marsden Hospital, London, SM2 5PT, UK. Electronic address: chris.parker@icr.ac.uk.
² Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
³ Medical Research Council Clinical Trials Unit at University College London, London, UK.
⁴ Genito-Urinary Cancer Research Group, Department of Surgery, The Christie Hospital, Manchester, UK.

PMID: 31498099
DOI: 10.1016/S0140-6736(19)31829-X

No abstract available

PubMed Disclaimer

Comment on

Radiotherapy for metastatic prostate cancer.
Gouda MA. Gouda MA. Lancet. 2019 Sep 7;394(10201):829. doi: 10.1016/S0140-6736(19)31782-9. Lancet. 2019. PMID: 31498097 No abstract available.
Radiotherapy for metastatic prostate cancer.
Aparicio A, Thall P, Logothetis C. Aparicio A, et al. Lancet. 2019 Sep 7;394(10201):829-830. doi: 10.1016/S0140-6736(19)31783-0. Lancet. 2019. PMID: 31498098 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Grants and funding

3804/CRUK_/Cancer Research UK/United Kingdom

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information